WuXi Biologics
2025.01.20
12:01
Hong Kong Stocks Midday Review: Hang Seng Index rose 2.33% and Hang Seng Technology Index rose 3.17%
At the close of Hong Kong stocks at noon, the Hang Seng Index rose 2.33% and the Hang Seng Technology Index rose 3.17%. Pharmaceutical stocks led the gains, with JD.com and WuXi AppTec rising more than 7%, Alibaba and Meituan rising more than 6%, and WuXi Biologics rising more than 5%.
09:44
Hong Kong-listed pharmaceutical stocks strengthened, with WuXi AppTec rising more than 5%
Hong Kong-listed pharmaceutical stocks strengthened, with WuXi AppTec rising more than 5%, followed by WuXi Biologics, CStone Pharmaceuticals, Corning Life Sciences, and Tigermed.
09:36
The Hong Kong stock biopharmaceutical sector rose in early trading, with WuXi AppTec (02359.HK) rising more than 5%, WuXi Biologics (02269.HK) rising more than 4%, BeiGene (06160.HK), Tiger Pharmaceuticals (03347.HK) and others following suit.
2025.01.14
09:22
Hong Kong stocks opened, the Hang Seng Index opened up 0.15%, and the Sci-Tech Index opened up 0.14%. WuXi Biologics (02269.HK) rose 3.55%, and WuXi Hexun (02268.HK) rose 3.46%.
09:22
Hong Kong stocks opened: Hang Seng Index opened 0.15% higher, Hang Seng Technology Index opened 0.14% higher
Hong Kong stocks opened, with the Hang Seng Index opening 0.15% higher and the Hang Seng Technology Index opening 0.14% higher. BeiGene and WuXi Biologics rose more than 3%.
2025.01.09
10:03
Hong Kong stocks related to pharmaceutical outsourcing concepts collectively strengthened, with WuXi Biologics (02269.HK) rising more than 4%, WuXi AppTec (02359.HK) rising more than 2%, Zhaoyan Pharmaceutical (06127.HK) and Tiger Pharmaceuticals (03347.HK) rising more than 1%.
2025.01.07
10:04
Hong Kong-listed pharmaceutical stocks fell, with Shandong Xinhua Pharmaceutical falling more than 5%
Hong Kong-listed pharmaceutical stocks fell, with Shandong Xinhua Pharmaceutical falling more than 5%, WuXi Biologics falling more than 4%, and WuXi AppTec, BeiGene, Junshi Biosciences and others following suit.
2024.12.30
10:01
Hong Kong-listed biopharmaceutical stocks rose during the session, with InnoCare Pharma (02359.HK) and WuXi AppTec (02359.HK) both rising by more than 4%, Tiger Pharmaceuticals (03347.HK) rising by more than 3.5%, GenScript Biotech (01548.HK), Zai Lab (09688.HK), WuXi Biologics (02269.HK), and BeiGene (06160.HK) all rising by more than 2%.
08:10
WuXi Biologics and Sino Biopharmaceuticals Enter into a Research Services Collaboration for “First-in-Class” Monoclonal Antibodies
On December 30, WuXi Biologics announced a research service cooperation agreement with Sino Biopharmaceuticals to support its discovery of a "First-in-Class" monoclonal antibody with an undisclosed target. According to the agreement, WuXi Biologics will provide integrated research services through antibody discovery technology platforms (such as single B cell technology platforms), generate antibodies based on targets specified by Sino Biopharmaceuticals, and conduct lead antibody discovery, optimization, and developability evaluation, etc., to screen out the best candidate monoclonal antibodies in the preclinical development stage. Sino Biopharmaceuticals will have exclusive rights to the monoclonal antibody and will be responsible for subsequent new drug clinical trial applications (INDs), clinical trials, and product commercialization. WuXi Biologics will receive corresponding payments based on the progress of project development and commercialization.
2024.12.20
08:15
WuXi Biologics and Duoxi Biopharma Enter into Research Services Collaboration with Aadi Bioscience for Three Innovative ADCs
On December 20, WuXi Biologics announced that it had reached a research service cooperation agreement with Hangzhou Duoxi Biotechnology Co., Ltd. and Aadi Bioscience to support Aadi in developing three new-generation antibody-drug conjugates (ADCs) in the preclinical stage. According to the terms of the agreement, Aadi will pay WuXi Biologics and Duoxi Bioscience a down payment of US$44 million, a development milestone payment of up to US$265 million, a commercial milestone payment of US$540 million, and a single-digit sales commission.
2024.12.19
09:24
Many stocks in the Hong Kong biopharmaceutical sector opened lower, with WuXi AppTec (02359.HK) opening down 2.78%, WuXi Biologics (02269.HK) opening down 2.77%, Tiger Pharmaceuticals (03347.HK), BeiGene (06160.HK) and others following suit.
2024.12.18
16:11
At the close of Hong Kong stocks, the Hang Seng Index closed up 0.83%, and the Hang Seng Tech Index closed up 1.82%. The biotechnology sector strengthened in the afternoon, with Ascletis Pharmaceuticals (01672.HK) closing up 19.33% and WuXi Biologics (02269.HK) closing up 2.73%.
2024.12.17
12:00
Hong Kong Stocks Midday Review: Hang Seng Index fell 0.39% Hang Seng Technology Index fell 0.49%
At the close of Hong Kong stocks at noon, the Hang Seng Index fell 0.39% and the Hang Seng Technology Index fell 0.49%. ZTE rose more than 7%, China Literature fell more than 5%, and WuXi Biologics fell more than 2%.
2024.12.09
17:32
Southbound funds made a large net purchase of 12.777 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), Tracker Fund Management and Alibaba-W received net purchases of HK$2.964 billion and HK$749 million respectively; WuXi Biologics had the largest net sales of HK$405 million; in terms of Hong Kong Stock Connect (Shenzhen), Tracker Fund Management and Hang Seng China Enterprises received net purchases of HK$2.664 billion and HK$782 million respectively; China National Offshore Oil Corporation had the largest net sales of HK$216 million.
16:10
Hong Kong stocks closed: Hang Seng Index rose 2.76% Hang Seng Technology Index rose 4.30%
Hong Kong stocks rose sharply in the late trading. As of the close, the Hang Seng Index rose 2.76%, the Hang Seng Technology Index rose 4.30%, and Chinese brokerage stocks and pharmaceutical stocks led the gains. China Tianrui Cement rose 1212.50%, China Merchants Securities rose more than 13%, and WuXi AppTec and WuXi Biologics rose more than 9%.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.

2025-01-31

White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.

2025-02-01

Apple (AAPL.O) said the Apple Pay outage has been resolved.

2025-01-29

Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.

2025-01-30

Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.

2025-02-03

ASIA TECH WIRE

Grasp technology trends

Download